Opportunities for CAR T-Cell Therapy in Solid Tumors

Video

Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.

"What is it about the solid tumor micro-environment that makes it challenging for T cells? One of the things is that it really is a tough environment for cells to survive in. The centers of solid tumors will become necrotic. They're very low-glucose, low-oxygen environments, a lot of down regulation of T cells. We came at things from that approach and said, 'Are there specific properties of a solid tumor micro-environment that we can arm the T cells to be able to survive better?'" —Geoffrey Hodge, chief executive officer of SOTIO BioTech US

Chimeric antigen receptor (CAR) T-cell therapy has proven to be efficacious for hematological indications, but its utility in solid tumors has been more of a challenge historically.

Many cell therapy developers are exploring combination therapies or secreting cytokines, but SOTIO is taking a different approach, according to Geoffrey Hodge, chief executive officer of SOTIO BioTech US.

"What is it about the solid tumor micro-environment that makes it challenging for T cells? One of the things is that it really is a tough environment for cells to survive in. The centers of solid tumors will become necrotic. They're very low-glucose, low-oxygen environments, a lot of down regulation of T cells," he told CGTL in an interview. "We came at things from that approach and said, 'Are there specific properties of a solid tumor micro-environment that we can arm the T cells to be able to survive better?'"

Hodge and Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, joined CGTL to discuss SOTIO, its 3 technology platforms, its pipeline of IL-15 Superagonists and antibody-drug conjugates, and the status of its clinical programs.

Related Videos
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Michael Kelly, PhD
Related Content
© 2024 MJH Life Sciences

All rights reserved.